JP2025078652A5 - - Google Patents

Info

Publication number
JP2025078652A5
JP2025078652A5 JP2025028446A JP2025028446A JP2025078652A5 JP 2025078652 A5 JP2025078652 A5 JP 2025078652A5 JP 2025028446 A JP2025028446 A JP 2025028446A JP 2025028446 A JP2025028446 A JP 2025028446A JP 2025078652 A5 JP2025078652 A5 JP 2025078652A5
Authority
JP
Japan
Prior art keywords
viral vector
acid sequence
promoter
nucleic acid
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025028446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025078652A (ja
Filing date
Publication date
Priority claimed from JP2018560974A external-priority patent/JP7632835B2/ja
Application filed filed Critical
Publication of JP2025078652A publication Critical patent/JP2025078652A/ja
Publication of JP2025078652A5 publication Critical patent/JP2025078652A5/ja
Pending legal-status Critical Current

Links

JP2025028446A 2016-05-20 2025-02-25 加齢関連疾患及び症状の遺伝子治療法 Pending JP2025078652A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662339182P 2016-05-20 2016-05-20
US62/339,182 2016-05-20
US201662421665P 2016-11-14 2016-11-14
US62/421,665 2016-11-14
JP2018560974A JP7632835B2 (ja) 2016-05-20 2017-05-22 加齢関連疾患及び症状の遺伝子治療法
JP2021194601A JP7315284B2 (ja) 2016-05-20 2021-11-30 加齢関連疾患及び症状の遺伝子治療法
JP2023044658A JP2023078338A (ja) 2016-05-20 2023-03-20 加齢関連疾患及び症状の遺伝子治療法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023044658A Division JP2023078338A (ja) 2016-05-20 2023-03-20 加齢関連疾患及び症状の遺伝子治療法

Publications (2)

Publication Number Publication Date
JP2025078652A JP2025078652A (ja) 2025-05-20
JP2025078652A5 true JP2025078652A5 (enExample) 2025-09-18

Family

ID=60326179

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018560974A Active JP7632835B2 (ja) 2016-05-20 2017-05-22 加齢関連疾患及び症状の遺伝子治療法
JP2021194601A Active JP7315284B2 (ja) 2016-05-20 2021-11-30 加齢関連疾患及び症状の遺伝子治療法
JP2023044658A Pending JP2023078338A (ja) 2016-05-20 2023-03-20 加齢関連疾患及び症状の遺伝子治療法
JP2025028446A Pending JP2025078652A (ja) 2016-05-20 2025-02-25 加齢関連疾患及び症状の遺伝子治療法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2018560974A Active JP7632835B2 (ja) 2016-05-20 2017-05-22 加齢関連疾患及び症状の遺伝子治療法
JP2021194601A Active JP7315284B2 (ja) 2016-05-20 2021-11-30 加齢関連疾患及び症状の遺伝子治療法
JP2023044658A Pending JP2023078338A (ja) 2016-05-20 2023-03-20 加齢関連疾患及び症状の遺伝子治療法

Country Status (9)

Country Link
US (2) US12281154B2 (enExample)
EP (1) EP3458585A4 (enExample)
JP (4) JP7632835B2 (enExample)
CN (2) CN117535350A (enExample)
AU (2) AU2017268469C1 (enExample)
BR (1) BR112018073861A2 (enExample)
CA (1) CA3025020A1 (enExample)
MX (2) MX2018014256A (enExample)
WO (1) WO2017201527A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110494151A (zh) * 2017-02-14 2019-11-22 耶路撒冷希伯来大学伊森姆研究发展有限公司 Naf-1衍生肽及其用途
CA3054942A1 (en) * 2017-03-17 2018-09-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression
EP3630160A1 (en) * 2017-05-24 2020-04-08 Universitat Autònoma De Barcelona Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence
CN111182915A (zh) 2017-08-15 2020-05-19 金德雷德生物科学股份有限公司 兽药用IgG Fc变体
EP3697428A4 (en) * 2017-10-20 2021-11-24 President And Fellows Of Harvard College ARTIFICIAL SECRETORS FOR THE PRODUCTION OF HETEROLOGICAL PROTEINS
WO2019113061A1 (en) * 2017-12-06 2019-06-13 Klogene Therapeutics, Inc. Compositions and methods for modulating gene expression
WO2020047472A1 (en) * 2018-08-30 2020-03-05 Research Institute At Nationwide Children's Hospital Gene therapy for the treatment of galactosemia
CN113194984A (zh) * 2018-10-18 2021-07-30 金德雷德生物科学股份有限公司 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体
WO2020106351A1 (en) * 2018-11-21 2020-05-28 Klogenix Llc Increasing gene expression
CN113227126A (zh) * 2018-11-26 2021-08-06 巴塞罗那自治大学 成纤维细胞生长因子21(fgf21)基因治疗
CN114127291A (zh) 2019-05-23 2022-03-01 克里斯蒂安娜保健服务公司 用于治疗癌症的nrf2基因敲除
JP7585237B2 (ja) 2019-05-23 2024-11-18 クリスティアナ ケア ジーン エディティング インスティテュート，インコーポレーテッド がんを処置するためのバリアントｎｒｆ２の遺伝子ノックアウト
AR119271A1 (es) 2019-06-11 2021-12-09 Shire Human Genetic Therapies Administración del vector viral adenoasociado para el tratamiento de enfermedades mediadas por la calicreína plasmática desregulada
US10653731B1 (en) * 2019-07-15 2020-05-19 Vigene Biosciences Inc. Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
KR102281858B1 (ko) * 2019-09-11 2021-07-26 주식회사 쎌바이오텍 유산균 유래 p8 단백질의 발현 컨스트럭트를 포함하는 대장 질환의 치료 또는 예방용 조성물
KR20220079857A (ko) * 2019-09-13 2022-06-14 루트거스, 더 스테이트 유니버시티 오브 뉴 저지 Aav-상용성 라미닌-링커 중합 단백질
JP7659550B2 (ja) 2019-10-23 2025-04-09 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アデノ随伴ウイルスベクターに基づく遺伝性血管浮腫のための遺伝子治療
CN110894508B (zh) * 2019-10-31 2021-08-06 内蒙古大学 一种调控白色脂肪棕色化的基因Adra1a的应用
JP7701359B2 (ja) * 2019-12-05 2025-07-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 変形性関節症の治療方法
JP7588466B2 (ja) * 2020-01-22 2024-11-22 旭化成メディカル株式会社 パルボウイルスの生産方法
WO2021222476A2 (en) * 2020-04-28 2021-11-04 President And Fellows Of Harvard College High efficiency gene delivery system
EP4149503A1 (en) * 2020-05-13 2023-03-22 Lysogene Compositions and methods for treating gm1 gangliosidosis and other disorders
US20230201306A1 (en) * 2020-05-26 2023-06-29 Universitat Autònoma De Barcelona Fibroblast growth factor 21 (FGF21) gene therapy for central nervous system disorders
CN114181944B (zh) * 2020-09-14 2023-10-03 中国科学院动物研究所 突变基因及构建短肢性侏儒症小型猪模型的方法和用途
WO2022115739A2 (en) * 2020-11-30 2022-06-02 Cellular Longevity, Inc. Lnp and liposome compositions for longevity in mammals and methods of using the same
EP4263614A1 (en) 2020-12-16 2023-10-25 Takeda Pharmaceutical Company Limited Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
KR102590276B1 (ko) * 2021-01-04 2023-10-16 부산대학교 산학협력단 조직 특이적 발현을 위한 융합 프로모터 및 이의 용도
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法
CN113088531B (zh) * 2021-03-25 2023-10-17 四川省药品检验研究院(四川省医疗器械检测中心) 牛源性成分定量分析标准质粒、制备及检测方法及应用
WO2022221291A2 (en) * 2021-04-12 2022-10-20 University Of Florida Research Foundation Incorporated Compositions and methods for treating obesity
JP2022169389A (ja) * 2021-04-27 2022-11-09 国立大学法人北海道大学 イヌＴＧＦ－β受容体ＩＩ
US20220401583A1 (en) * 2021-06-16 2022-12-22 BioViva USA, Inc. Treatment of age-related cognitive decline using genetically modified viral vectors
US20230018934A1 (en) * 2021-07-16 2023-01-19 Genflow Biosciences Srl Method of in vivo administration of the coding sequence of the sirt6 gene via adeno-associated virus
EP4408482A4 (en) * 2021-09-29 2025-11-12 Sirt6 Ltd METHOD OF TREATING A DISEASE
CN114921480A (zh) * 2022-06-09 2022-08-19 国科宁波生命与健康产业研究院 一种骨细胞Terc基因敲除小鼠模型的构建方法
WO2024064785A2 (en) * 2022-09-21 2024-03-28 Rejuvenate Bio Gene therapy methods for familial partial lipodystrophy
WO2024064796A2 (en) * 2022-09-21 2024-03-28 Rejuvenate Bio Gene therapy methods for arrhythmogenic cardiomyopathy
EP4590693A2 (en) * 2022-09-21 2025-07-30 Rejuvenate Bio Inc Gene therapy methods for treating mitral valve disease
CN116790610B (zh) * 2023-05-18 2024-09-20 四川大学 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物
EP4566618A1 (en) * 2023-12-06 2025-06-11 ADvantage Therapeutics, Inc. Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight
WO2025109173A1 (en) 2023-11-22 2025-05-30 Advantage Therapeutics, Inc. Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
WO1998048024A1 (en) 1997-04-18 1998-10-29 Biogen, Inc. Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins
US7622300B2 (en) * 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
US7419829B2 (en) * 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
AU2003209226A1 (en) * 2002-01-11 2003-07-30 Michael Tennant Adiponectin gene therapy
US8158589B2 (en) * 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
US7511056B2 (en) * 2004-11-10 2009-03-31 Eli Lilly And Company TGF-β inhibitors
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
ATE505489T1 (de) * 2005-04-22 2011-04-15 Lilly Co Eli Tgf-beta-1-spezifische antikörper
DE102005061840A1 (de) * 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
US20070292922A1 (en) * 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
WO2008088401A2 (en) * 2006-09-13 2008-07-24 The Trustees Of Columbia University In The City Of New York Methods for identifying, or assaying for agents that increase beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass
EP2171062A1 (en) * 2007-06-15 2010-04-07 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
US8236557B2 (en) 2008-05-28 2012-08-07 University Of Missouri-Columbia Hybrid-AAV vectors to deliver large gene expression cassette
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
PL2542590T5 (pl) * 2010-03-05 2020-08-10 The Johns Hopkins University Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
AR083445A1 (es) * 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
DK2455104T3 (da) * 2010-11-19 2013-10-14 Universitaetsklinikum Freiburg Biofunktionaliserede stimulusafhængige opløselige PEG-hydrogeler
EP2548570A1 (en) * 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
JP2014526441A (ja) * 2011-08-31 2014-10-06 アムジエン・インコーポレーテツド １型糖尿病の治療における使用のためのｆｇｆ２１
JO3476B1 (ar) * 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية
CN103203027A (zh) * 2011-11-03 2013-07-17 阳明大学 用于治疗和预防老化相关症状的方法和组分
US9422561B2 (en) 2012-01-24 2016-08-23 Bar-Ilan University Treatment of disease by modulation of SIRT6
CN103665166A (zh) * 2012-09-03 2014-03-26 福又达生物科技股份有限公司 犬融合干扰素
WO2014152993A1 (en) * 2013-03-14 2014-09-25 The Board Of Regents Of The University Of Oklahoma Use of klotho nucleic acids or proteins for treatment of diabetes and diabetes-related conditions
EP3129043A4 (en) * 2014-04-08 2017-11-15 University of Southern California Polypeptide compositions with type vii collagen fibronectin type iii- like repeats and treatment methods for wound closure and healing
KR20150135148A (ko) * 2014-05-23 2015-12-02 주식회사 제넥신 Pd-l1 융합 단백질 및 이의 용도
KR102854572B1 (ko) * 2014-10-24 2025-09-02 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
EP3334750B1 (en) * 2015-08-11 2022-10-05 Anie Philip Peptidic tgf-beta antagonists

Similar Documents

Publication Publication Date Title
JP2025078652A5 (enExample)
JP2022033855A5 (enExample)
IL299325B2 (en) Acid-alpha glucosidase variants and uses thereof
JP2019519221A5 (enExample)
JP2020114235A5 (enExample)
US6365403B1 (en) High-efficiency AAV helper functions
JP2020520643A5 (enExample)
IL292264B2 (en) aav transfer cassette
JP2023065516A5 (enExample)
JPWO2021067448A5 (enExample)
JPWO2020033473A5 (enExample)
JPWO2019165050A5 (enExample)
JPWO2021050614A5 (enExample)
JPWO2020243651A5 (enExample)
JPWO2021076911A5 (enExample)
JPWO2020186207A5 (enExample)
JPWO2021113642A5 (enExample)
JPWO2020237130A5 (enExample)
JPWO2022066911A5 (enExample)
JPWO2020252136A5 (enExample)
JPWO2022028472A5 (enExample)
JPWO2019143803A5 (enExample)
JPWO2022183052A5 (enExample)
JPWO2022018171A5 (enExample)
RU2022111695A (ru) Выделенная нуклеиновая кислота, которая кодирует слитый белок на основе FVIII-BDD и гетерологичного сигнального пептида, и ее применение